Clinical Trial Update: HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update notes the withdrawal of a Phase 1/2 study evaluating decitabine with venetoclax and navitoclax for relapsed or refractory pediatric hemato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• Dacogen (decitabine)
• Navitoclax (navitoclax)
• Venclexta (venetoclax)

Snippet

Sponsor: Princess Maxima Center for Pediatric Oncology | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1, Phase 2 | Status: WITHDRAWN